Berlin, Germany
Prosoma is a global medical company focusing on Digital Therapeutics (DTx) for oncology. Their flagship product, Living Well, is a clinically-validated, self-care mobile application designed to support cancer patients' behavioral and mental health needs to improve their quality of life and overall outcomes. The company's solutions not only aim to enhance treatment effectiveness and provide essential data for both pharmaceutical companies and healthcare providers but also generate savings for healthcare systems.
Established in 2017 and headquartered in Germany, Prosoma aspires to lead the field of Digital Therapeutics for oncology by offering comprehensive, tailored solutions for cancer patients. Their goal is to create a portfolio of medical software products that combine expertise in medicine and technology to address the entire behavioral support needs of cancer patients, ultimately contributing to an improved quality of life.
Prosoma has garnered credibility through partnerships with renowned organizations for clinical trials and large-scale commercial partners in the USA and Germany. The company is also participating in various acceleration programs such as Accelerate Cambridge, Incredibles, and the HealthHub at the University of California. To ensure compliance, Prosoma meets EU Medical Device Regulations: ISO 13485, ISO 62304, and ISO 27001.
The most recent funding received by Prosoma was a grant investment at 06 June 2023. The investors involved in this round were not specified.
